Abdera Therapeutics

R&D

Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.